Emerging Infectious Disease Diagnostics Market Report 2026

Emerging Infectious Disease Diagnostics Market Overview

• Emerging Infectious Disease Diagnostics market size has reached to $24.34 billion in 2025 • Expected to grow to $38.54 billion in 2030 at a compound annual growth rate (CAGR) of 9.6% • Growth Driver: Impact Of Rising Zoonotic Diseases On Emerging Infectious Disease Diagnostics Market • Market Trend: Advancing High-Throughput Multiplex Diagnostic Innovation For Emerging Diseases • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Emerging Infectious Disease Diagnostics Market?

Emerging infectious disease diagnostics refers to the advanced methods and tools used to detect new or re-emerging infectious diseases caused by pathogens such as viruses, bacteria, or parasites. These diagnostics leverage cutting-edge technologies such as molecular testing, genomics, and rapid assays to identify infections quickly and accurately, improving public health responses. They are crucial in monitoring and controlling outbreaks, as well as in developing targeted treatments and vaccines. The main infection types of emerging infectious disease diagnostics are viral, bacterial, fungal, and others. Viral infections are diseases caused by viruses, which are tiny pathogens that replicate inside the host's cells. The disease includes respiratory infections, gastrointestinal infections, and sexually transmitted infections (STIs), and the technologies are polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), next-generation sequencing (NGS), immunodiagnostics, and others. The different applications are laboratory testing and point-of-care testing and are used by various end-users such as hospitals and clinics, diagnostics laboratories, and others.

What Is The Emerging Infectious Disease Diagnostics Market Growth Forecast?

The emerging infectious disease diagnostics market size is expected to see strong growth in the next few years. It will grow to $38.54 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to increasing focus on pandemic preparedness, rising adoption of next-generation sequencing diagnostics, expansion of decentralized testing models, growing integration of ai-driven diagnostic analytics, increasing government funding for disease monitoring. Major trends in the forecast period include increasing deployment of rapid molecular diagnostic platforms, rising adoption of point-of-care testing solutions, growing integration of genomic surveillance tools, expansion of multiplex diagnostic assays, enhanced focus on early outbreak detection.

Global Emerging Infectious Disease Diagnostics Market Segmentation

1) By Infection Type: Viral, Bacterial, Fungal, Other Infections 2) By Disease Type: Respiratory Infections, Gastrointestinal Infections, Sexually Transmitted Infections (STIs), Other Disease Types 3) By Technology: Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), Next-Generation Sequencing (NGS), Immunodiagnostics, Other Technologies 4) By Application: Laboratory Testing, Point-of-Care Testing 5) By End-User: Hospitals And Clinics, Diagnostics Laboratories, Other End-Users Subsegments: 1) By Viral: Respiratory Viruses, Hepatitis Viruses, HIV and Retroviruses, Arboviruses, Herpesviruses, Gastrointestinal Viruses, Emerging Viral Infections 2) By Bacterial: Tuberculosis (TB), Methicillin-Resistant Staphylococcus Aureus (MRSA), Escherichia Coli (E. coli) Infections, Streptococcus and Pneumococcus Infections, Clostridium Infections, Neisseria, Emerging Drug-Resistant Bacteria 3) By Fungal: Candidiasis, Aspergillosis, Cryptococcosis, Histoplasmosis, Coccidioidomycosis, Pneumocystis Pneumonia (PCP), Emerging Fungal Infections 4) By Other Infections: Parasitic Infections, Protozoan Infections, Prion Diseases, Helminthic Infections, Non-Pathogenic or Environmental Infections

What Is The Driver Of The Emerging Infectious Disease Diagnostics Market?

The rising incidence of zoonotic diseases is expected to propel the growth of the emerging infectious disease diagnostics market going forward. Zoonotic diseases refer to infections that can be transmitted from animals to humans, caused by bacteria, viruses, parasites, or fungi. The rising incidence of zoonotic diseases is primarily due to increased human-wildlife interactions, habitat destruction, and global travel, which facilitate pathogen transmission across species. Emerging infectious disease diagnostics help manage zoonotic diseases by enabling early detection and accurate identification of pathogens, allowing for prompt intervention, effective treatment, and better containment of disease outbreaks, thereby reducing transmission from animals to humans. For instance, in June 2025, according to the Centers for Disease Control and Prevention, a US-based government public-health agency, 48 states and the District of Columbia reported 2,770 human arboviral disease cases in 2023, up from 1,247 cases in 2022, including 2,022 hospitalizations (73%) and 208 deaths (8%), with West Nile virus being the most commonly reported domestic arboviral disease in 2023, accounting for 2,628 cases (95%). Therefore, the rising incidence of zoonotic diseases is driving the emerging infectious disease diagnostics industry.

Key Players In The Global Emerging Infectious Disease Diagnostics Market

Major companies operating in the emerging infectious disease diagnostics market are Roche Diagnostics, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Becton Dickinson and Company, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Hologic Inc., Illumina Inc., bioMérieux SA, QuidelOrtho Corporation, Bio-Rad Laboratories, Inc., Qiagen N.V., DiaSorin S.p.A., Randox Laboratories Ltd., Meridian Bioscience Inc., Sekisui Diagnostics LLC, Copan Diagnostics, Co-Diagnostics Inc., T2 Biosystems Inc.

Global Emerging Infectious Disease Diagnostics Market Trends and Insights

Major companies operating in the emerging infectious disease diagnostics market are focusing on developing innovative solutions, such as temperature-activated generation of signal (TAGS) technology, to enhance rapid detection, high-throughput screening, and improved outbreak response capabilities. TAGS technology is an advanced multiplex PCR method that uses controlled temperature activation to generate optical signals for simultaneous identification of multiple pathogens from a single sample, enabling capabilities such as broad syndromic testing, faster turnaround times, and optimized laboratory workflows. For instance, in September 2024, F. Hoffmann-La Roche AG, a Switzerland-based diagnostics and biotechnology company, launched the cobas Respiratory flex test, a TAGS-powered molecular diagnostic designed to detect up to 12 common respiratory viruses from one patient sample, featuring automated high-throughput analysis, flexible pathogen panel configuration, and compatibility with cobas 5800, 6800, and 8800 systems. cobas Respiratory flex improves timely detection of infectious agents, strengthens clinical decision-making, and supports better preparedness for emerging disease threats

What Are Latest Mergers And Acquisitions In The Emerging Infectious Disease Diagnostics Market?

In May 2024, Bruker Corporation, a US-based provider of scientific instruments and diagnostic solutions, acquired ELITechGroup for $942 million (€870 millions). With this acquisition, Bruker gains access to ELITech’s sample to answer molecular diagnostics platforms such as InGenius and BeGenius and a broad infectious disease assay portfolio, thereby enhancing Bruker’s molecular diagnostics and in vitro diagnostics capabilities and expanding its reach in hospital and clinical laboratory infectious disease testing globally. ELITechGroup is a France-based in vitro diagnostics company specializing in molecular diagnostics, biomedical systems, and microbiology.

Regional Outlook

North America was the largest region in the emerging infectious disease diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Emerging Infectious Disease Diagnostics Market?

The emerging infectious disease diagnostics market consists of revenues earned by entities by providing services such as laboratory testing, diagnostic tool development, clinical interpretation of test results, surveillance and reporting, and the provision of telehealth consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The emerging infectious disease diagnostic market also includes sales of rapid test kits, polymerase chain reaction (PCR) machines, molecular diagnostic assays, sequencing platforms, point-of-care diagnostic devices, and biosensors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Emerging Infectious Disease Diagnostics Market Report 2026?

The emerging infectious disease diagnostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the emerging infectious disease diagnostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.